INTRODUCTION
Ovarian carcinoma cells exhibit distinct cell surface antigens that distinguish them from cells of normal adult tissues including ovary (1-7). Tumor-associated antigens (TAA)1 have provided promising targets for immunodetection and immunotherapy of ovarian cancer in clinical studies and in animal models (8) (9) (10) (11) . Circulating TAA have been found in the blood of some ovarian cancer patients at a time when their tumors were still potentially curable by surgery alone (12) . More advanced disease can respond dramatically to cytoreductive surgery and chemotherapy, but even following a complete clinical response the tumor generally recurs within 2-5 yr (13, 14) . In this setting, immunotherapy might eliminate the relatively small number of tumor cells that remain after more conventional treatment. Clinical trials to date have used active immunotherapy with immunostimulants and tumor cell vaccines (15) (16) (17) (18) (19) . Work in animal systems suggests, however, that ovarian carcinoma may be one of the tumors that will respond to treatment with antisera directed against TAA (8, 9, 11) .
In the past, heteroantisera against human TAA have usually required extensive absorbtion to remove activity against nonmalignant tissues. Absorbed antisera are often of low titer and specificity has varied between different preparations. With the development of somatic cell hybridization techniques, large quantities of high titered monoclonal antibody can now be produced that does not require absorption (20) . Moreover, each hybridoma produces a chemically homogeneous immunoglobulin that permits the selection of antibodies of a particular functional subclass as well as of a unique specificity. During our earlier studies, conventional rabbit heteroantisera were prepared against human and murine ovarian carcinomas (7) (8) (9) 21) . In our report a murine monoclonal IgGl immunoglobulin has been developed with specificity for human ovarian carcinoma. Isolation of lymphocyte subpopulations. Human peripheral blood mononuclear cells were isolated from healthy volunteer donors by Ficoll-Hypaque density gradient centrifugation (22) . Unfractionated mononuclear cells were separated into surface immunoglobulin-positive (slg+) and surface immunoglobulin-negative (sIg-) populations by Sephadex G-200 anti-F(ab)2 chromatography (23) with modifications designed to minimize monocyte retention by the column (24) . Peripheral blood mononuclear cells were preincubated at 37°C for 1 h to remove cytophilically-bound serum IgG (25) , and cells were applied to the anti-F(ab)2 column and fractionated as outlined (23 (26) . Normal human monocytes were obtained by adherence to plastic culture dishes as described (27) .
METHODS
Cell lines. Six (36) .
RESULTS
The most promising clone isolated to date, designated OC125, produces an IgGI immunoglobulin which binds to 6 of 6 epithelial ovarian carcinoma cell lines (Table I) and to cryopreserved tumor cells from ascites fluid in 7 of 11 ovarian cancer patients. OC125 reacts with only 1 of 14 tumor cell lines established from a variety of nonovarian neoplasms (Table I ). The one nonovarian tumor cell line to which OC125 binds, MEL394, was derived from a melanoma. The antibody did not, however, bind to three other melanoma lines.
Extensive studies have failed to demonstrate binding of OC125 to nonmalignant tissues. The OC125 immunoglobulin was selected originally for reactivity with the OVCA433 ovarian tumor cell line and for lack of reactivity with a B lymphocyte line (LAZ 444) established from the same individual (Fig. 1) (Table II) .
By flow cytometer analysis, OC125 does not react with enzymatically dissociated cells from adult or fetal ovary and does not bind to a cell line established from nonmalignant adult ovary. The majority of malignant ovarian tumors that develop in the adult, however, are thought to arise from the germinal epithelium that covers the ovarian surface and lines subcapsular cysts. OC125 might react with a normal differentiation antigen that is associated with the surface epithelium, Fig. 2A, B) . By contrast, bright fluorescence was associated with the epithelial component in sections of ovarian carcinomas from five of nine patients (Fig. 3A) . The brightest staining was on the luminal surface of the malignant epithelium, which formed papillary projections and invasive glandlike structures (Fig. 4A,  B) . When control sections were incubated with a murine antihuman IgM monoclonal immunoglobulin of the same subclass (clone 287), staining with fluoresceinated goat antimouse immunoglobulin failed to produce significant fluorescence (Fig. 3B) . Because OC125 binds to antigen with sufficient avidity to permit examination of tissue sections by indirect immunofluorescence, we have examined the reactivity of the antibody with cryostat sections from a number of normal adult tissues (Table III) . No reactivity could be detected with any of the normal tissues tested including uterus, breast, fallopian tube, skin, lung, liver, spleen, or kidney, nor did OC125 stain any of 12 carcinomas from other sites (Table III) . In addition OC125 has failed to react with a variety of hematopoietic and lymphoreticular tissues which can be analyzed in suspension by indirect immunofluorescence using the flow cytometer, including allogeneic T cells, B cells, null cells, monocytes, AB erythrocytes, bone marrow, tonsil, and lymph node cells (Table IV) . (4) , kidney (3) , colon (2) , lung (1) , uterus (1), and testes (1).
t Includes samples of uterine corpus (3) and cervix (3), fallopian tubes (2) , breast (2), kidney (4, one fetal), lung (2), liver (3) , spleen (3), and skin (3).
To test the possibility that OC125 detects carcinoembryonic antigen (CEA), the specific OC125 antibody or the irrelevant clone 287 was incubated with '25I-labeled CEA. Immunoglobulin was precipitated with zirconyl phosphate gel. No more labeled CEA was coprecipitated with OC125 than with a nonspecific monoclonal reagent (Table V) . Similar numbers of counts were precipitated by zirconyl phosphate gel in the absence of immunoglobulin. Labeled CEA did coprecipitate, as expected, in the presence of specific heteroantiserum, and precipitation of labeled CEA could be inhibited with nonlabeled CEA (Table V) . The relationship ofthe antigen recognized by OC125 to other ovarian tumor-associated antigens defined by conventional heteroantisera remains to be determined. Although the identity of the moieties with which OC125 reacts must await the outcome of biochemical analysis, the antibody did not coprecipitate radiolabeled CEA. This is an important control in that circulating CEA can be detected in the peripheral blood of at least 40% of ovarian cancer patients during the course of their illness (37) . Although elevated CEA is most frequently associated with tumors of mucinous histology, it can be associated with ovarian carcinomas that exhibit other morphologies.
Monoclonal antibodies are now being developed against antigens associated with several different human malignancies (30, (38) (39) (40) . Similar reagents that react specifically with human ovarian carcinoma may prove particularly useful both for diagnosis and treatment of this disease. To date prognosis in ovarian carcinoma has been correlated with the degree of differentiation, clinical stage, and histological type of the neoplasm (41) . Among serous cystadenocarcinomas of similar grade, 0C125 has bound to some tumor specimens, but not to others. The presence or absence of antigens may permit more precise classification and prognostication in the ovarian carcinomas, as has been the case in studies of acute leukemia (42) and of lymphoma (43) .
Cytological analysis of ascites specimens is a continuing problem for the pathologist. Antibodies that identify malignant tumor cells of ovarian origin in pleural or peritoneal fluid may prove valuable in surgical staging and in determining the probable site of primary malignancy. Considering the difficulties encountered in evaluating response to therapy, several investigators have attempted to develop immunoassays for the detection of tumor-associated antigen in peripheral blood or body fluids of patients with known ovarian carcinoma. The availability of large amounts of essentially pure antibody should facilitate development of such assays, provided that an antibody can be isolated of appropriate affinity as well as specificity for an antigen that is shed from the tumor cell surface. Antigens that are not shed may still prove useful as targets for in situ diagnosis using radiolabeled antibodies and for therapy using monoclonal antibodies that have been conjugated with cytotoxic agents or with isotopes at high specific activity.
Recent work from our laboratory suggests that treatment with a combination of specific heteroantiserum and immunostimulant is more effective than treatment with either single agent for eliminating ovarian tumor cells in a murine model for serotherapy (11) . Synergy between antibody and Corynebacterium parvum appears to depend, at least in part, on the ability of the immunostimulant to attract, arrest, and activate peritoneal cells that mediate antibody-dependent cytotoxicity. With the availability of monoclonal reagents, it should be possible to evaluate a similar approach in clinical trials of intraperitoneal immunotherapy using antibodies of appropriate specificity and subclass in combination with immunostimulants.
